Replies to post #186856 on Biotech Values

[iwfal]

AGTC’s AAV-vector technology has improved in the eight years since the AMD deal was struck with Genzyme, so I don’t consider the Genzyme history a significant blemish for AGTC.

I had hoped that when I looked at the presentations etc I would see good data on HOW the technology has improved - e.g. better vector as per pre-clinical in vivo data, better understanding of where to inject. But they don't seem to address this.

That said, I haven't looked hard for papers yet - and haven't digested the S1 (my bad!).